Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective multicenter phase IV study of omalizumab in Chinese adolescents with chronic spontaneous urticaria inadequately controlled by H1 antihistamines
CTR20233527Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Started Mar 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20233527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233527.